


 Cite this: *RSC Adv.*, 2020, **10**, 13293

Enzyme encapsulation by protein cages

 Soumyananda Chakraborti,^{†a} Ting-Yu Lin,^b Sebastian Glatt^b and Jonathan G. Heddle^{*a}

Protein cages are hollow protein shells with a nanometric cavity that can be filled with useful materials. The encapsulating nature of the cages means that they are particularly attractive for loading with biological macromolecules, affording the guests protection in conditions where they may be degraded. Given the importance of proteins in both industrial and all cellular processes, encapsulation of functional protein cargoes, particularly enzymes, are of high interest both for *in vivo* diagnostic and therapeutic use as well as for *ex vivo* applications. Increasing knowledge of protein cage structures at high resolution along with recent advances in producing artificial protein cages means that they can now be designed with various attachment chemistries on their internal surfaces – a useful tool for cargo capture. Here we review the different available attachment strategies that have recently been successfully demonstrated for enzyme encapsulation in protein cages and consider their future potential.

 Received 28th December 2019
 Accepted 10th March 2020

DOI: 10.1039/c9ra10983h

rsc.li/rsc-advances

1 Introduction

Nanoscale structures consisting of a protein shell surrounding a central cavity are known as protein cages. Such structures can be used for protective encapsulation of cargoes which may

otherwise be degraded. Nature has exploited this admirably, most obviously in the case of viruses. These typically have an approximately spherical protein shell, called a capsid, that can protect a nucleic acid genome from external degradation machineries. The virus capsid does an excellent job of shielding its genome and specifically and efficiently delivering it to target cells where it can be released and copied. Viruses then, act as the gold standard exemplar of the potential of protein cages. Indeed, viruses have been modified to take advantage of these capabilities, most notably where the viral genome has been replaced with other nucleic acids of interest for gene therapy. Currently a number of virus vectors are being tested for

^aBionanoscience and Biochemistry Laboratory, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow 30-387, Poland. E-mail: jonathan.heddle@uj.edu.pl

^bMax Planck Research Group, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow 30-387, Poland

[†] Current address: Centre for Nanosciences Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham AIMS Ponekkara P. O., Kochi, Kerala – 682041, India.



Soumyananda Chakraborti (Soumya) is currently an assistant professor at Amrita Vishwa Vidyapeetham Centre for Nanoscience and Molecular Medicine. Before joining his present position he was a member of Bionanoscience and Biochemistry Laboratory headed by Professor Jonathan Heddle. His present research objective is to develop DNA/protein based functional nano-materials. Soumya obtained his PhD from the Bose Institute, India where he studied protein nanoparticle interactions. He has authored more than 30 publications. His major research areas are protein engineering, protein nanoparticle interaction, chemical biology, DNA-origami, synthetic biology and nano-biotechnology.

obtained his PhD from the Bose Institute, India where he studied protein nanoparticle interactions. He has authored more than 30 publications. His major research areas are protein engineering, protein nanoparticle interaction, chemical biology, DNA-origami, synthetic biology and nano-biotechnology.



Ting-Yu Lin obtained her PhD from the department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan. Her interests are in nucleic acid and nucleic acid-regulatory proteins. She was recently awarded the Taiwanese Ministry of Science Technology postdoctoral fellowship, which supports her working at the Max Planck Laboratory led by Dr Sebastian Glatt.



potential use in this way¹ and adeno-associated virus mediated transgene expression of human coagulation factor FVIII, as a treatment of hemophilia B has met with some success.²

However, for therapeutic^{3,4} or industrial⁵ use, a more radical redesign is required to expand the library of possible cargoes beyond nucleic acids, to include proteins. This is because, in simple terms, for any biological process it is usually proteins (*i.e.* enzymes, hormones *etc.*) that carry out the bulk of the important functionality. Thus, for example, it is desirable to be able to deliver proteins to cells for therapy. Delivering a protein rather than its respective coding information may also have the added benefit of avoiding unwanted side effects associated with the latter including deregulation and horizontal gene transfer. Proteins, in the form of enzymes, are also used in many industrial processes.⁶ Examples include manganese peroxidase (MnP) for biodegradation of phenolic compounds and amidase for degradation of nitrile-containing waste.⁷

Typically, protein cages are highly stable and retain their structure at, for proteins, extremely high temperatures. In addition, by nature of their constrained volume, cargoes are maintained physically close to one another and cannot diffuse away. These are favourable characteristics in several scenarios. For example, in *in vivo* therapeutics, “naked” proteins may not be used in many cases as they would not survive in the body long enough to reach the target site, being for example degraded by proteases, denatured or cleared. Under these circumstances, a thermostable protein shell can act as a protective “armour”. This stabilisation effect may also be beneficial for enzymes used as industrial catalysts: if a higher temperature favours non-enzymatic parts of the process, the ability of an enzyme to also function at such higher temperatures may lead to an increased overall efficiency. In addition, having multiple enzymes that are involved in a reaction physically close to each other could conceivably increase local concentrations and reaction rates. Apart from these potential applied uses, putting proteins into cages in a tuneable manner

which controls their density may allow the investigation of more basic research questions such as the effects of protein crowding.⁸

These perceived benefits have led to the development of protein cages able to house other proteins in their cavity. One way this can be achieved is by modification of existing natural cage proteins. In this review, we focus on recent studies that have successfully demonstrated enzyme encapsulation using protein cages. Given that there are many different kinds of protein cages available, three main categories of encapsulation methods are summarized, namely (i) electrostatic interactions, (ii) affinity and (iii) genetic fusion (Table 1).

2 Electrostatic interactions

Electrostatic interactions rely on the interior of the protein cage and the protein cargo carrying opposing charges and is one of the most common methods for protein cargo encapsulation. Natural packaging of genetic material inside viruses for example utilizes this type of interaction. This can be exploited and viruses devoid of their genetic cargo (called virus like particles, VLP) constitute the bulk of protein cages used for protein encapsulation to date. Early demonstrations of protein encapsulation employing proven or probable electrostatic interactions were shown for a number of cages including cowpea chlorotic mottle virus (CCMV),⁹ lumazine synthase (LS)¹⁰ and MS2 bacteriophage.¹¹ In recent years, the number of enzyme cargoes encapsulated *via* electrostatic effects has significantly expanded (Fig. 1).

2.1 CCMV

Work on CCMV was an early example showing that a large protein could be encapsulated inside a protein cage.¹² Later it was shown that cargoes can be efficiently loaded inside CCMV using electrostatic interactions between the highly positively charged N-terminus of coat protein (CP) and the overall negative surface charged cargo.^{9,13} However, one of the major drawbacks



Sebastian Glatt, born in Austria, studied genetics and microbiology at the University of Vienna. After his PhD thesis in molecular oncology at the pharmaceutical industry, he moved to EMBL Heidelberg and transformed from a cell biologist into a protein/RNA biochemist and structural biologist. Since September 2015 he leads an independent Max Planck Research Group at the Malopolska Centre of Biotechnology (MCB), the postgraduate research centre for life science of the Jagiellonian University in Krakow, Poland. He is also deputy director for scientific affairs at the MCB and head of the “National Cryo-EM facility” at the neighbouring Solaris synchrotron.



Jonathan Heddle completed his PhD in biochemistry at the University of Leicester. After a postdoctoral fellowship at Yokohama City University and two PI positions at Tokyo Institute of Technology and RIKEN he moved to his current position at the Malopolska Centre of Biotechnology where he leads the Bionanoscience and Biochemistry Laboratory. He aims to understand and build

artificial and natural bionano machines with a focus on protein and nucleic acid structures. This includes designed DNA origamis and novel protein cages. He hopes to continue to advance both basic developments and applications of these structures in the future.



Review

Table 1 Summary of recent studies on encapsulated enzymes and the employed encapsulation methods

Cage	Cargo	Cage size (nm)	Encapsulation method	Reference
AfFtn	SOD	12	Maleimide-mediated conjugation	63
AfFtn	CA ^a , RA ^b , KE ^b	12	Electrostatic/supercharging	27
AfFtn	Luciferase	12	Fusion to AfFtn monomer	81
TmFtn	Lysozyme	12	Electrostatic/diffusion	8
Horse spleen ferritin	ATHase	12	Electrostatic/diffusion	29
AaLS-13	TEVp, RuBisCO ^c , CA ^a , APEX2	40	Electrostatic/supercharging	18–20
CCMV	GOx ^d , GCK ^d	28	Electrostatic/SS-nucleotide	13
ELP-CCMV	Lipase CalB	28	SrtA-mediated coupling	42
ELP-CCMV	T4 lysozyme	28	SrtA-mediated coupling	43
MS2 phage	TnaA & FMO	28	SpyTag/SpyCatcher	49
MS2 phage	GFP-neg, PhoA-neg	28	Electrostatic/negative peptide	11
HBV (Cp149)	β -Glucosidase	32, 36	Ca ²⁺ -mediated binding	52
Bacterial encapsulin	DyP	23	Unique anchoring sequence	61 and 62
P22	CelB, Hyd-1	~60	Fusion/scaffold protein tagging	74 and 75
P22	CYP	~60	Fusion/scaffold protein tagging	76
Vault	MnP	~34	Fusion to INT domain	82

^a CA: human carbonic anhydrase II. ^b RA, KE: evolved artificial enzymes ((retro-) aldolase RA95.5-8F and Kemp eliminase HG3.17). ^c RuBisCO: ribulose-1,5-bisphosphate carboxylase/oxygenase. ^d GOx: glucose oxidase; GCK: gluconokinase.

of this method is the overall cargo loading capacity. Using diffusion-controlled electrostatics, a rather weak interaction force, usually results in packing density of cargo proteins per cage well below the theoretically achievable maximum based on volume calculations. To increase the strength of the electrostatic interaction between the partners, the cargo encapsulation method was further improved.¹³ In this new approach, cargo protein was coated with highly negatively charged polyanionic templates such as single stranded DNA, and then assembled with positively charged CCMV coat protein (Fig. 1a). This not only led to an improvement in loading capacity but also allowed capturing of two sequentially active enzymes inside a single CCMV. This permitted a complete enzymatic reaction cascade to take place inside the cage.¹³

2.2 Lumazine synthase

LS is an enzyme involved in riboflavin (vitamin B2) biosynthesis.¹⁴ LS from *Aquifex aeolicus* (AaLS-wt) possess an unique




Fig. 1 Examples of protein cargo encapsulation inside protein cages mediated by electrostatic interactions. Centre: Concept of electrostatically-mediated cargo encapsulation. (a) Attachment of DNA (red) to gluconokinase (green) provides sufficient negative charge to facilitate encapsulation in CCMV (grey). Figure reproduced with permission from ref. 13 (<https://pubs.acs.org/doi/10.1021/jacs.6b10948>). (b) AaLS-13 has an internal negative charge allowing capture of TEV protease (TEVp) tagged with positively supercharged GFP. By altering the charge of the tag on the substrates (S) their entry into the cage and therefore cleavage by the protease is controlled. Figure reproduced with permission from ref. 19 (<https://pubs.acs.org/doi/full/10.1021/jacs.7b11210>). (c) Mixing of individual TmFtn subunits (left, blue cartoon representation) and supercharged GFP (green, surface representation) results in encapsulation of GFP in the assembled ferritin cage (right, blue surface representation) under favourable salt conditions. The image was adapted and modified with permission from ref. 8 (<https://pubs.acs.org/doi/full/10.1021/acsnano.7b07669>). Further permissions related to the material excerpted should be directed to the ACS.

cage-like quaternary architecture, and has been developed as a biotechnology tool including extensive protein cargo encapsulations based on electrostatic interactions.¹⁵ To facilitate electrostatic interactions for cargo loading, the lumen of AaLS-wt was engineered to generate AaLS-neg, a variant with high internal negative charge. AaLS-neg was shown capable of efficiently capturing a deca-arginine tagged GFP.¹⁰ This variant was used to encapsulate a toxic protease from human immunodeficiency virus (HIV) tagged with a deca-arginine, protecting the *E. coli* host cells from its toxic action.¹⁶ Interestingly, the fact that encapsulation of the cargo was required for host cell survival in this case meant that the system could be used to evolve cages with greater cargo capturing capability, yielding the new variant termed AaLS-13. The concept of using a positively charged tag to direct cargo into the LS cavity was developed further with the use of a so-called supercharged GFP carrying a high positive charge (+36GFP). This could be loaded into assembled AaLS-13 cages with high efficiency. Additionally, the interaction with +36GFP accelerates cage assembly of the pentameric capsomer units.¹⁷ +36GFP could also be used as a fusion tag, which when appended to a number of different enzymes was able to direct their encapsulation.^{18–22} Amongst these, an engineered ascorbate peroxidase (APEX2) was proven to perform constrained polymerization of compound 3,3-



diaminobenzidine (DAB) inside the LS cage²⁰ while encapsulation of Tobacco Etch Virus (TEV) protease allowed construction of a substrate-sorting nanoreactor (Fig. 1b).

2.3 Ferritin

Ferritin is an iron storage protein found in almost all organisms except yeast.²³ Like many cage proteins, ferritins spontaneously assemble and are stable, requiring relatively harsh conditions for disassembly.^{24,25} For capturing or releasing active proteins which may often be quite fragile, this represents a challenge. Some archaeal ferritins offer a potential solution as they show reversible assembly in response to relatively mild changes in salt concentration (salt-dependency). This is seen for example in ferritin from *Archaeoglobus fulgidus* (AfFtn) which also shows an unusual symmetry (tetrahedral, rather than octahedral as seen in most other ferritins).^{23,26} This advantage along with the fact that AfFtn has a negatively charged interior was exploited to encapsulate enzymes tagged with +36GFP.²⁷

One possible disadvantage of AfFtn is that it has 4 large holes in its surface^{23,26} which are potentially large enough for proteases to enter and degrade guests or for smaller protein cargoes to be released. This problem was partially solved by using ferritin from *Thermotoga maritima* (TmFtn), which was also found to be salt-dependent but had octahedral symmetry and lacked the large holes. TmFtn was shown able to encapsulate +36GFP (Fig. 1c) and protein cargoes were protected from proteases. In fact, encapsulated lysozyme showed increased activity, most likely due to protein crowding effects.⁸ The fact that TmFtn containing active enzyme can be assembled into a superlattice in the presence of gold nanoparticles was exploited to generate an enzymically active superlattice.²⁸

Another early demonstration of protein encapsulation in ferritin was performed using horse spleen ferritin. It was shown that this ferritin can incorporate an artificial transfer hydrogenase (ATHase) during reassembly of the cage triggered by pH changes.²⁹ Given no covalent or engineered affinity interactions between cargo and cage, electrostatic effects likely play a role.²⁹

3 Encapsulation via affinity methods

The affinity strategy (Fig. 2) is mainly achieved by genetic engineering of cage proteins to create specific interactions with selected cargoes. An example is complementary coiled-coiled sequences on cage and guest proteins.^{30,31} There are also naturally occurring examples of affinity interactions between cage and cargoes which can be mimicked for protein encapsulation.^{32,33} Some recent examples are explained in detail in this section.

3.1 SrtA-mediated coupling

Sortase A (SrtA) is a 206 amino acid long transpeptidase found in Gram-positive bacteria which is involved in catalysing the attachment of proteins to the cell wall.³⁴ The enzyme is able to specifically recognize a LPXTG cell wall sorting signal (where X can be any amino acid).^{35,36} It cleaves the bond between tyrosine and glycine residues to form the LPXT-SrtA intermediate.




Fig. 2 Scheme of protein cargo encapsulation inside protein cages by affinity methods. Centre: Concept of affinity-based cargo encapsulation. (a) SrtA-conjugation-mediated mechanism in CCMV. Glycine-ELP (purple) was fused to the N-terminus of CCMV whereas the CaIB cargo protein was fused to the sorting peptide (LPETG, green). The image was reproduced from ref. 42 with permission from The Royal Society of Chemistry. (b) SpyTag and SpyCatcher-mediated mechanism in MS2. The wild type MS2 (green) was genetically engineered to produce an version (brick red) having the SpyTag (orange) inserted between S53 and A54. The cargo protein (blue) was fused with SpyCatcher. The image was reproduced with permission from ref. 49 Copyright 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. (c) A dual expression system produces a truncated capsid protein from HBV either not fused (Cp149, red) or fused (Cp144-DL-PP, blue) to C20W for construction of mosaic capsids (top left). In the presence of Ca^{2+} ions (black) the α -helical C20W binds TR2C (bottom left). GFP fused to TR2C can be encapsulated into the capsid via the C20W-TR2C interaction (right). The image was used with permission from ref. 52 Copyright 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. (d) DyP-E (blue) can be encapsulated in encapsulin. In tandem with GOx this forms a catalytic cascade producing green-coloured ABTS radicals in the presence of glucose. The image was used with permission from ref. 61 (<https://doi.org/10.1021/acsnano.7b07669>). Further permissions related to the figure should be directed to the ACS.

Subsequently this intermediate joins to the amino group of a glycine residue on host pentaglycine crossbridges via an amide bond, resulting in anchoring of the surface protein to the host cell wall. The sortase A and LPXTG peptide system was firstly identified in *Staphylococcus aureus* as part of the pathogen infection mechanism.^{37,38}

The SrtA system has clear biotechnology potential in attaching together two discrete proteins including protein cage/cargo combinations.³⁹ This was demonstrated using elastin-like-polypeptide (ELP)⁴⁰ modified CCMV (ELP-CCMV)⁴¹ where ELP facilitates capsid assembly at pH 7.5 triggered by high salt concentration⁴² (Fig. 2a). The resulting salt-induced icosahedral ELP-CCMV capsid has a diameter of 20–30 nm (triangular number (T) = 1). To exploit the sortase reaction, an additional glycine was introduced at the N-termini of ELP-CCMV capsid proteins (G-ELP-CCMV).⁴² Meanwhile, a SrtA recognition site peptide was genetically appended to the C-terminus of cargo



proteins. The G-ELP-CCMV was then covalently linked to the cargo proteins equipped with the peptide in the presence of SrtA to form the covalently coupled product (cargo-LPETG-ELP-CCMV). The co-assembly of *Candida Antarctica* lipase B-ELP-CCMV (CalB-ELP-CCMV) and G-ELP-CCMV in capsids was demonstrated and showed that a maximum of two copies of the CalB enzyme can be encapsulated in the ELP-CCMV capsid cavity. This low loading efficiency is probably caused by steric constraints.⁴²

A second generation of ELP-CCMV was further developed using the sortase-based encapsulation method to load cargo proteins without the need for high salt conditions (~2 M NaCl).⁴³ This strategy used metal ions to stabilize the assembly process and bypass the high salt concentration effect. Here, a hexahistidine tag was added to ELP-CCMV at the N-terminus and the presence of divalent nickel ions resulted in local clustering⁴⁴ of the ELP-CCMV capsid proteins to subsequently trigger the assembly at pH 7.5 without the necessity for high salt concentrations. Using this approach, it is possible to encapsulate four copies of T4-lysozyme despite the fact that it has a cationic surface charge.

One disadvantage noted in this study of the second generation of ELP-CCMV is that they cannot be disassembled upon demand as would be expected by the addition of EDTA which presumably would chelate the nickel ions to disrupt the interaction. A possible explanation is that the action of EDTA could be hampered by the crowding effect inside the cavity.⁴³

3.2 SpyTag/SpyCatcher targeting

SpyTag/SpyCatcher is one of the most robust protein biotechnology tools for protein ligation⁴⁵ which has been further developed for affinity purification.⁴⁶ Extracellular proteins of Gram-positive bacteria such as pilins and adhesin, contain spontaneously formed isopeptide bonds that help stabilize protein structures.⁴⁷ Such a strategy is found, for example, within immunoglobulin-like domains CnaB1 or CnaB2. SpyTag (13 aa) and SpyCatcher (116 aa) were generated by splitting the CnaB2 domain of the fibronectin-binding protein FbaB from *Streptococcus pyogenes*. This peptide-protein pair can spontaneously form a covalently-linked complex. The system has been widely used for bioconjugation.⁴⁸

The system was introduced to bacteriophage MS2 capsid to encapsulate multiple enzymes for cascade reactions with possible applications for use as a nanoreactor⁴⁹ (Fig. 2b). The SpyTag sequence (GSGAHIVMVDAYKPTKSG) was inserted into the MS2 capsid protein (insertion site: S53A54) to produce MS2-Spy. This insertion does not affect the capsid assembly (outer diameter = 27 nm, $T = 3$). Meanwhile, cargo proteins were genetically fused to the SpyCatcher tag peptide which allowed the cargo to be covalently linked to the interior of MS2 capsid during the co-expression and co-purification process. The resulting modified MS2-Spy forms into two products; elongated nanotubes and spheres, however, only the sphere capsid contains the SpyCatcher-tagged cargo. Encapsulation of two-enzymes was demonstrated: pyridoxal phosphate (PLP)-dependent tryptophanase (TnaA) and nicotinamide adenine

dinucleotide phosphate (NADPH)-dependent monooxygenase (FMO), responsible for biosynthesis of the commercially relevant dye Indigo.

As an additional test, the two enzymes were further constructed in a polycistronic operon and their order (TnaA then FMO or FMO then TnaA) was tested to obtain optimal expression and encapsulation. Having the TnaA ORF prior to the FMO ORF was found to result in better production of the dye. Enzyme encapsulation not only helped with increased indigo production but also stabilized the enzymes to retain activity for up to seven days comparing to free enzymes.

3.3 Calcium-mediated cargo-loading and release

Hepatitis B virus (HBV)-VLP primarily forms icosahedral capsids with 120 core protein homodimers ($T = 4$)⁵⁰ along with a small population of $T = 3$ icosahedral symmetry (90 homodimers).⁵¹ The assembly domain (Cp149) can be expressed in *E. coli* and also self-assembles into capsids morphologically equivalent to wild type HBV-VLP.⁵⁰ Protein cargoes can be packaged into HBV-VLP *via* fusion to its C-terminus or *via* non-specific loading during self-assembly. This Cp149 capsid forming property was used to achieve efficient and specific cargo encapsulation *via* a Ca^{2+} -dependent method⁵² (Fig. 2c). The loading mechanism is based on the Ca^{2+} -mediated binding⁵³ (nanomolar affinity) between the C-terminal domain of calmodulin (TR2C) and an α -helical sequence derived from the membrane plasma Ca^{2+} pump (C20W).

Introducing C20W to the C-terminus of Cp149 while fusing the cargo proteins to TR2C facilitates encapsulation during self-assembly *in vitro*. The model cargo protein was a β -glucosidase from *Clostridium cellulovorans* (CcBglA) which still retains its activity while being encapsulated inside the capsid. Two advantages of Ca^{2+} -mediated guest loading are (i) calcium ions are biocompatible, with lower toxicity compared to many other metal ions. (ii) The interaction is reversible, meaning that the cargo can be unloaded from the interior surface. This detachment of cargo can be achieved either by the addition of EDTA or dialysis against decalcified buffer.

3.4 Spontaneous cargo loading

Spontaneous guest cargo loading of protein cages *via* natural targeting peptides has been demonstrated in LS^{54,55} and some bacterial microcompartments (BMCs), such as *Salmonella enterica* ethanolamine utilization bacterial microcompartment^{32,33} or encapsulins.⁵⁶

Encapsulins are protein-based nanocompartment organelles found in prokaryotes.⁵⁷ They share a similar protein fold to the Hong Kong 97-like virion, which is one of the most well-characterized protein fold architectures in virus capsids.⁵⁸ Encapsulins form icosahedral particles ($T = 1$) 23 nm in diameter and are known to be used in nature as containers for protein cargoes.^{32,56} There are many other encapsulins found in different bacteria and archaea.^{57,59,60} Here we specifically discuss the encapsulin from *Brevibacterium linens* which has recently been demonstrated to encapsulate enzymes^{61,62} with the natural cargo being a dye-decolorizing peroxidase (DyP) (Fig. 2d). The



mechanism of cargo capture is *via* an interaction between the unique anchoring sequence at the C-terminus of DyP and a defined region of the encapsulin interior surface.

The natural DyP cargo was replaced with a foreign cargo which was fused to the DyP C-terminal anchoring sequence.^{61,62} Teal fluorescence protein (TFP) was used and cargo loading efficiency was 10–12 TFP per capsid. In the case of the original cargo, DyP, only one copy locates in each encapsulin even though the encapsulation capacity ($2.6 \times 10^6 \text{ \AA}^3$) can accommodate considerably more though shape and oligomerization state of the cargo may limit loading.

DyP-loaded encapsulin can be fixed on a glass surface without affecting enzyme activity which constitutes an advantage for biosensor applications.⁶¹ For *in vivo* applications, *B. linens* encapsulin has other advantages, such as lysine residues on its outer surface that are available for chemical modification.

3.5 Maleimide-mediated cargo conjugation

The classical way of achieving encapsulation in ferritin is by electrostatic interactions (see Section 2.3). However, an alternative approach has been demonstrated employing conjugation using AfFtn.⁶³ Cargo loading is specifically controlled by maleimide-mediated conjugation between AfFtn and target protein. The assembly of AfFtn is dependent on the ionic strength of the buffer. This allows the cargo protein to be conjugated onto AfFtn first under phosphate-buffered saline conditions (PBS with 0.15 M NaCl) followed by assembly of AfFtn nanocages in high salt buffer (1 M NaCl). The formed nanocages then undergo a crosslinking procedure to stabilise the cage and are conjugated with antibodies against plasma-membranal vesicle-associated protein (Plvap) for endothelial drug targeting. This research aimed to deliver superoxidase dismutase (SOD) to caveolae, the flask-shaped invaginations of plasma membranes abundant in the pulmonary endothelium as an anti-inflammatory agent. Because the internal diameter of caveolae stomata apertures is considered to be less than 30 nm, AfFtn cages (outer diameter = 10–12 nm, with an 8 nm diameter cavity) are sufficiently small for targeted delivery. SOD-carrying-antibody-modified-AfFtn cages were confirmed to be delivered into cells and mostly located in endosomes and lysosomes. Subsequent animal studies have shown that the enzyme-containing antibody-modified-AfFtn provides protection against lipopolysaccharide-induced inflammation.

4 Gene fusion

This section deals with protein cargo encapsulation utilizing direct genetic fusion either to protein cage monomers or some auxiliary subunits necessary for assembly. Genetic fusion is normally carried out in such a way that the cargo should face the internal lumen of the cage (Fig. 3). This method is advantageous compared to other methods in terms of achieving an efficient encapsulation ratio and retention of the cargo.⁶⁴ One of the major challenges is to control the extent of cargo loading inside protein cage, as potentially every monomer will carry a cargo, possibly leading to steric clashes and inhibition of cage

formation. A patchwork assembly method addresses this problem by mixing cargo-fused monomer with unmodified monomer in different ratios to generate cages with different numbers of cargo in different protein cages, such as CCMV and AaLS.^{65,66} There are several instances of protein cages known where cargo encapsulation is carried out using genetic fusion.⁶⁷ Among these perhaps the most notable is the P22 bacteriophage cage VLP where protein cargo encapsulation has almost exclusively been achieved using genetic fusion.⁶⁸

4.1 Bacteriophage P22

Bacteriophage P22 is a double stranded DNA virus belonging to the Podoviridae family and infects the bacterium *Salmonella typhimurium*.⁶⁹ Phage P22 assembles into a $T = 7$ icosahedral capsid (known as a “procapsid”) with a 50 nm central cavity into which DNA is subsequently packaged.^{69,70} Assembly of the CP requires the presence of an additional assembly chaperone “scaffold protein” (SP). P22 VLP is structurally highly similar to the procapsid (PC) form of the bacteriophage and is normally formed by 420 CP and 100–300 SPs. SPs attach to the capsid inner wall mainly by electrostatic interaction. Protein cargo encapsulation inside P22 is then achieved *via* fusion of cargoes to SP wherein modified cargo-SP, unmodified-SP and coat protein are co-expressed and assembled inside *E. coli* (Fig. 3a). Using this approach, several studies have demonstrated P22 as




Fig. 3 Scheme of protein cargo encapsulation inside cage by fusion methods. Centre: Concept of fusion-based cargo encapsulation. (a) Schematic showing P22 VLP assembly from individual subunits (coat and scaffolding protein), scaffold protein is first genetically modified (fused) with cargo protein and then co-expressed and assembled in presence of coat protein to generate the cage inside *E. coli*. The image was reproduced from ref. 80 with permission from Elsevier. (b) Schematic showing ferritin-fused with cargo and encapsulation of the cargo during assembly.⁸¹ (c) Schematic showing encapsulation of MnP in vault *via* its fusion with the INT domain. Reprinted (adapted) with permission from ref. 82 (<https://doi.org/10.1021/acsnano.5b04073>). Copyright (2015) American Chemical Society.



the carrier for direct cargo encapsulation.⁷¹ Examples of encapsulated proteins include fluorescence protein (GFP and mCherry),⁷² alcohol dehydrogenase D (AdhD),⁶⁸ β -glycosidase (CelB) (a truncated P22 was employed to form the protein cages),^{73,74} NiFe hydrogenase (Hyd-1)⁷⁵ and cytochrome P450 (CYP).⁷⁶ It is also possible to encapsulate several different enzymes inside a single P22 capsid and to use them to perform a cascade reaction with a good efficiency.⁷⁷ Such a reaction has also been demonstrated in P22 which is itself arranged into a higher order, superlattice structure.^{64,78–80}

4.2 Ferritin

Although ferritin is known for encapsulation *via* electrostatic interactions, AfFtn can also be genetically modified in order to accommodate several protein cargoes *via* fusion. GFP, Renilla luciferase, and truncated versions of horseradish peroxidase have all been fused to the ferritin C-terminus leading to their presence in the cavity after ferritin assembly⁸¹ (Fig. 3b). Unexpectedly, it was observed that the protein cargo can be easily released from the cage by mild alteration of pH followed by a cleavage reaction. In addition, the encapsulated cargo appears resistant to thermal, chaotropic, and proteolytic stress and in some cases appeared to result in several-fold increase in protein folding efficiency.⁸¹

4.3 Vault

Vault is another example of protein cage where cargo loading was achieved using direct genetic fusion⁸² (Fig. 3c). Vault is a large (roughly 13 MDa) protein assembly with dimensions of approximately $67 \times 40 \times 40$ nm. It is found in almost all eukaryotes and possesses a unique architecture. Its main physiological function in eukaryotes is still unknown. Almost all known vaults consist of one major protein component known as the major vault protein (MVP), with minor components including poly(ADP-ribose) polymerase (VPARP), telomerase and small non-translated RNA.⁸³ Structural and biophysical studies have shown that MVP and VPARP interact through involvement of a particular domain known as interaction domain (INT) present on VPARP. The domain consists of 161 amino acids and resides on the C-terminus of VPARP. As VPARP binding to MVP is facilitated by the INT domain, it was initially predicted and later demonstrated that it can be used as a tag for direct protein capture inside of the vault particle.⁸⁴ Because of its unique architecture and its large cavity size, the vault cage has been widely used for cargo encapsulation of numerous molecules including therapeutics, small molecules and polymers.^{83,85} Recently it was used to load MnP for bioremediation. The enzyme was packaged inside vault by genetically fusing it with INT-domain, and then encapsulation was achieved *via* high affinity interaction between the INT domain and vault interior.⁸²

5 Conclusions and perspectives

The growing library of molecular tools allowing capture of cargoes within protein cages will widen the possible

combinations of cages and contents that can be paired together. In turn, this will lead to an increased breadth of potential applications for enzyme-filled cages. Combined with modifications to the exterior of protein cages this may allow the development of cages able to deliver therapeutic enzymes to particular tissues and cells. It is notable that all of the above-described examples are guest loading into (modified) naturally occurring protein cages. The structure of natural protein cages may have intrinsic limits to the extent or type of modification that can be carried out. In recent years, artificial protein cages that do not exist in nature have been designed and realised in a range of sizes^{86–88} with unusual protein-protein interfaces and triggerable disassembly properties.^{89–91} Little work has yet been carried out in adding protein cargoes to these artificial cages, but their programmability should allow bespoke functionalities. In addition, artificial cages will allow the use of all the capture strategies outlined above as well as further capture strategies which may not be compatible with a given natural cage. As natural and artificial protein cages carrying useful enzyme cargoes are developed further we may expect to see them integrated into more sophisticated ensembles with a suite of capabilities ensuring desired stability and positioning of reacting components for industrial catalysis. Alternatively they may be used for therapeutic applications targeting and release of the cargo with correct localisation and timing.

Conflicts of interest

JGH is named as an inventor on a patent application related to protein-cage assembly construction. He is also the founder of and holds equity in nCage Therapeutics LLC, which aims to commercialise protein cages for therapeutic applications.

Acknowledgements

We thank Dr Yusuke Azuma for his constructive comments and discussions. This work was supported by a National Science Centre (NCN, Poland) grant no. 2016/20/W/NZ1/00095 (Symfonia-4) to J. G. H., the Homing program (Homing/2016-2/14; T.-Y. L.), the Homing program (Homing/2017-3/22; S. C.) from the Foundation for Polish Science and the Ministry of Science and Technology (MOST, Taiwan) fellowship funding (108-2917-I-564-043-; T.-Y. L.).

References

- 1 K. Lundstrom, *Diseases*, 2018, **6**, 42.
- 2 H. T. Spencer, B. E. Riley and C. B. Doering, *Haemophilia*, 2016, **22**, 66–71.
- 3 E. Blanco, H. Shen and M. Ferrari, *Nat. Biotechnol.*, 2015, **33**, 941–951.
- 4 A. C. Anselmo and S. Mitragotri, *Bioeng. Transl. Med.*, 2019, **4**, e10143.
- 5 X. Zhou, W. Xu, G. Liu, D. Panda and P. Chen, *J. Am. Chem. Soc.*, 2010, **132**, 138–146.
- 6 M. V. Arbige, J. K. Shetty and G. K. Chotani, *Trends Biotechnol.*, 2019, **37**, 1355–1366.



- 7 R. Singh, M. Kumar, A. Mittal and P. K. Mehta, *3 Biotech*, 2016, **6**, 174.
- 8 S. Chakraborti, A. Korpi, M. Kumar, P. Stepien, M. A. Kostianen and J. G. Hedde, *Nano Lett.*, 2019, **19**, 3918–3924.
- 9 L. Sanchez-Sanchez, R. D. Cadena-Nava, L. A. Palomares, J. Ruiz-Garcia, M. S. Koay, J. J. Cornelissen and R. Vazquez-Duhalt, *Enzyme Microb. Technol.*, 2014, **60**, 24–31.
- 10 F. P. Seebeck, K. J. Woycechowsky, W. Zhuang, J. P. Rabe and D. Hilvert, *J. Am. Chem. Soc.*, 2006, **128**, 4516–4517.
- 11 J. E. Glasgow, M. A. Asensio, C. M. Jakobson, M. B. Francis and D. Tullman-Ercek, *ACS Synth. Biol.*, 2015, **4**, 1011–1019.
- 12 M. Comellas-Aragones, H. Engelkamp, V. I. Claessen, N. A. Sommerdijk, A. E. Rowan, P. C. Christianen, J. C. Maan, B. J. Verduin, J. J. Cornelissen and R. J. Nolte, *Nat. Nanotechnol.*, 2007, **2**, 635–639.
- 13 M. Brasch, R. M. Putri, M. V. de Ruiter, D. Luque, M. S. Koay, J. R. Caston and J. J. Cornelissen, *J. Am. Chem. Soc.*, 2017, **139**, 1512–1519.
- 14 A. Bacher, S. Eberhardt, M. Fischer, K. Kis and G. Richter, *Annu. Rev. Nutr.*, 2000, **20**, 153–167.
- 15 Y. Azuma, T. G. W. Edwardson and D. Hilvert, *Chem. Soc. Rev.*, 2018, **47**, 3543–3557.
- 16 B. Worsdorfer, K. J. Woycechowsky and D. Hilvert, *Science*, 2011, **331**, 589–592.
- 17 B. Worsdorfer, Z. Pianowski and D. Hilvert, *J. Am. Chem. Soc.*, 2012, **134**, 909–911.
- 18 R. Frey, S. Mantri, M. Rocca and D. Hilvert, *J. Am. Chem. Soc.*, 2016, **138**, 10072–10075.
- 19 Y. Azuma, D. L. V. Bader and D. Hilvert, *J. Am. Chem. Soc.*, 2018, **140**, 860–863.
- 20 R. Frey, T. Hayashi and D. Hilvert, *Chem. Commun.*, 2016, **52**, 10423–10426.
- 21 Y. Azuma, R. Zschoche, M. Tinzl and D. Hilvert, *Angew. Chem., Int. Ed.*, 2016, **55**, 1531–1534.
- 22 Y. Azuma and D. Hilvert, in *Protein Scaffolds*, ed. A. K. Udit, Humana Press, New York, NY, 2018, pp. 39–55.
- 23 G. Jutz, P. van Rijn, B. Santos Miranda and A. Boker, *Chem. Rev.*, 2015, **115**, 1653–1701.
- 24 M. Liang, K. Fan, M. Zhou, D. Duan, J. Zheng, D. Yang, J. Feng and X. Yan, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 14900–14905.
- 25 K. Yoshizawa, Y. Mishima, S. Y. Park, J. G. Hedde, J. R. Tame, K. Iwahori, M. Kobayashi and I. Yamashita, *J. Biochem.*, 2007, **142**, 707–713.
- 26 K. W. Pulsipher and I. J. Dmochowski, *Isr. J. Chem.*, 2016, **56**, 660–670.
- 27 S. Tetter and D. Hilvert, *Angew. Chem., Int. Ed. Engl.*, 2017, **56**, 14933–14936.
- 28 M. A. Kostianen, P. Hiekkataipale, A. Laiho, V. Lemieux, J. Seitsonen, J. Ruokolainen and P. Ceci, *Nat. Nanotechnol.*, 2012, **8**, 52–56.
- 29 M. Hestericová, T. Heinisch, M. Lenz and T. R. Ward, *Dalton Trans.*, 2018, **47**, 10837–10841.
- 30 I. J. Minten, L. J. A. Hendriks, R. J. M. Nolte and J. J. L. M. Cornelissen, *J. Am. Chem. Soc.*, 2009, **131**, 17771–17773.
- 31 I. J. Minten, V. I. Claessen, K. Blank, A. E. Rowan, R. J. M. Nolte and J. J. L. M. Cornelissen, *Chem. Sci.*, 2011, **2**, 358–362.
- 32 M. B. Quin, S. A. Perdue, S.-Y. Hsu and C. Schmidt-Dannert, *Appl. Microbiol. Biotechnol.*, 2016, **100**, 9187–9200.
- 33 S. Choudhary, M. B. Quin, M. A. Sanders, E. T. Johnson and C. Schmidt-Dannert, *PLoS One*, 2012, **7**, e33342.
- 34 H. Ton-That, S. K. Mazmanian, K. F. Faull and O. Schneewind, *J. Biol. Chem.*, 2000, **275**, 9876–9881.
- 35 O. Schneewind, P. Model and V. A. Fischetti, *Cell*, 1992, **70**, 267–281.
- 36 A. P. A. Hendrickx, W. J. B. van Wamel, G. Posthuma, M. J. M. Bonten and R. J. L. Willems, *J. Bacteriol.*, 2007, **189**, 8321–8332.
- 37 S. K. Mazmanian, *Science*, 1999, **285**, 760–763.
- 38 O. Schneewind, A. Fowler and K. Faull, *Science*, 1995, **268**, 103–106.
- 39 H. Mao, S. A. Hart, A. Schink and B. A. Pollok, *J. Am. Chem. Soc.*, 2004, **126**, 2670–2671.
- 40 M. B. van Eldijk, J. C. Wang, I. J. Minten, C. Li, A. Zlotnick, R. J. Nolte, J. J. Cornelissen and J. C. van Hest, *J. Am. Chem. Soc.*, 2012, **134**, 18506–18509.
- 41 L. Schoonen, R. J. M. Maas, R. J. M. Nolte and J. C. M. van Hest, *Tetrahedron*, 2017, **73**, 4968–4971.
- 42 L. Schoonen, R. J. M. Nolte and J. C. M. van Hest, *Nanoscale*, 2016, **8**, 14467–14472.
- 43 L. Schoonen, S. Maassen, R. J. M. Nolte and J. C. M. van Hest, *Biomacromolecules*, 2017, **18**, 3492–3497.
- 44 M. B. van Eldijk, L. Schoonen, J. J. L. M. Cornelissen, R. J. M. Nolte and J. C. M. van Hest, *Small*, 2016, **12**, 2476–2483.
- 45 B. Zakeri, J. O. Fierer, E. Celik, E. C. Chittock, U. Schwarz-Linek, V. T. Moy and M. Howarth, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, E690–E697.
- 46 I. N. A. Khairil Anuar, A. Banerjee, A. H. Keeble, A. Carella, G. I. Nikov and M. Howarth, *Nat. Commun.*, 2019, **10**, 1734.
- 47 H. J. Kang, F. Coulbaly, F. Clow, T. Proft and E. N. Baker, *Science*, 2007, **318**, 1625–1628.
- 48 S. C. Reddington and M. Howarth, *Curr. Opin. Chem. Biol.*, 2015, **29**, 94–99.
- 49 T. W. Giessen and P. A. Silver, *Chembiochem*, 2016, **17**, 1931–1935.
- 50 S. Singh and A. Zlotnick, *J. Biol. Chem.*, 2003, **278**, 18249–18255.
- 51 A. Zlotnick, N. Cheng, J. F. Conway, F. P. Booy, A. C. Steven, S. J. Stahl and P. T. Wingfield, *Biochemistry*, 1996, **35**, 7412–7421.
- 52 R. Lizatovic, M. Assent, A. Barendregt, J. Dahlin, A. Bille, K. Satzinger, D. Tupina, A. J. R. Heck, S. Wennmalm and I. Andre, *Angew. Chem., Int. Ed. Engl.*, 2018, **57**, 11334–11338.
- 53 T. Vorherr, P. James, J. Krebs, A. Enyedi, D. J. McCormick, J. T. Penniston and E. Carafoli, *Biochemistry*, 2002, **29**, 355–365.
- 54 Y. Azuma, R. Zschoche and D. Hilvert, *J. Biol. Chem.*, 2017, **292**, 10321–10327.
- 55 X. Han and K. J. Woycechowsky, *Biochemistry*, 2017, **56**, 6211–6220.



- 56 C. Cassidy-Amstutz, L. Oltrogge, C. C. Goings, A. Lee, P. Teng, D. Quintanilla, A. East-Seletsky, E. R. Williams and D. F. Savage, *Biochemistry*, 2016, **55**, 3461–3468.
- 57 M. Sutter, D. Boehringer, S. Gutmann, S. Günther, D. Prangishvili, M. J. Loessner, K. O. Stetter, E. Weber-Ban and N. Ban, *Nat. Struct. Mol. Biol.*, 2008, **15**, 939–947.
- 58 N. G. Abrescia, D. H. Bamford, J. M. Grimes and D. I. Stuart, *Annu. Rev. Biochem.*, 2012, **81**, 795–822.
- 59 H. Moon, J. Lee, J. Min and S. Kang, *Biomacromolecules*, 2014, **15**, 3794–3801.
- 60 C. A. McHugh, J. Fontana, D. Nemecek, N. Cheng, A. A. Aksyuk, J. B. Heymann, D. C. Winkler, A. S. Lam, J. S. Wall, A. C. Steven and E. Hoiczky, *EMBO J.*, 2014, **33**, 1896–1911.
- 61 R. M. Putri, C. Allende-Ballester, D. Luque, R. Klem, K. A. Rousou, A. Liu, C. H. Traulsen, W. F. Rurup, M. S. T. Koay, J. R. Caston and J. Cornelissen, *ACS Nano*, 2017, **11**, 12796–12804.
- 62 J. Snijder, O. Kononova, I. M. Barbu, C. Utrecht, W. F. Rurup, R. J. Burnley, M. S. Koay, J. J. Cornelissen, W. H. Roos, V. Barsegov, G. J. Wuite and A. J. Heck, *Biomacromolecules*, 2016, **17**, 2522–2529.
- 63 V. V. Shuvaev, M. Khoshnejad, K. W. Pulsipher, R. Y. Kiseleva, E. Arguiri, J. C. Cheung-Lau, K. M. LeFort, M. Christofidou-Solomidou, R. V. Stan, I. J. Dmochowski and V. R. Muzykantov, *Biomaterials*, 2018, **185**, 348–359.
- 64 W. M. Aumiller, M. Uchida and T. Douglas, *Chem. Soc. Rev.*, 2018, **47**, 3433–3469.
- 65 W. F. Rurup, F. Verbij, M. S. T. Koay, C. Blum, V. Subramaniam and J. J. L. M. Cornelissen, *Biomacromolecules*, 2014, **15**, 558–563.
- 66 Y. Azuma, M. Herger and D. Hilvert, *J. Am. Chem. Soc.*, 2018, **140**, 558–561.
- 67 D. Diaz, A. Care and A. Sunna, *Genes*, 2018, **9**, 370.
- 68 D. P. Patterson, P. E. Prevelige and T. Douglas, *ACS Nano*, 2012, **6**, 5000–5009.
- 69 M. M. Suhanovsky and C. M. Teschke, *Virology*, 2015, **479–480**, 487–497.
- 70 G. C. Lander, L. Tang, S. R. Casjens, E. B. Gilcrease, P. Prevelige, A. Poliakov, C. S. Potter, B. Carragher and J. E. Johnson, *Science*, 2006, **312**, 1791–1795.
- 71 D. P. Patterson, in *Protein Scaffolds*, ed. A. K. Udit, Humana Press, New York, NY, 2018, pp. 11–24.
- 72 A. O’Neil, P. E. Prevelige, G. Basu and T. Douglas, *Biomacromolecules*, 2012, **13**, 3902–3907.
- 73 D. P. Patterson, B. Schwarz, K. El-Boubbou, J. van der Oost, P. E. Prevelige and T. Douglas, *Soft Matter*, 2012, **8**, 5000–5009.
- 74 K. McCoy, E. Selivanovitch, D. Luque, B. Lee, E. Edwards, J. R. Castón and T. Douglas, *Biomacromolecules*, 2018, **19**, 3738–3746.
- 75 P. C. Jordan, D. P. Patterson, K. N. Saboda, E. J. Edwards, H. M. Miettinen, G. Basu, M. C. Thielges and T. Douglas, *Nat. Chem.*, 2015, **8**, 179–185.
- 76 L. Sánchez-Sánchez, A. Tapia-Moreno, K. Juárez-Moreno, D. P. Patterson, R. D. Cadena-Nava, T. Douglas and R. Vazquez-Duhalt, *J. Nanobiotechnol.*, 2015, **13**, 66.
- 77 D. P. Patterson, B. Schwarz, R. S. Waters, T. Gedeon and T. Douglas, *ACS Chem. Biol.*, 2013, **9**, 359–365.
- 78 M. Uchida, K. McCoy, M. Fukuto, L. Yang, H. Yoshimura, H. M. Miettinen, B. LaFrance, D. P. Patterson, B. Schwarz, J. A. Karty, P. E. Prevelige, B. Lee and T. Douglas, *ACS Nano*, 2017, **12**, 942–953.
- 79 K. McCoy, M. Uchida, B. Lee and T. Douglas, *ACS Nano*, 2018, **12**, 3541–3550.
- 80 E. Selivanovitch and T. Douglas, *Curr. Opin. Virol.*, 2019, **36**, 38–46.
- 81 S. Deshpande, N. D. Masurkar, V. M. Girish, M. Desai, G. Chakraborty, J. M. Chan and C. L. Drum, *Nat. Commun.*, 2017, **8**, 1442.
- 82 M. Wang, D. Abad, V. A. Kickhoefer, L. H. Rome and S. Mahendra, *ACS Nano*, 2015, **9**, 10931–10940.
- 83 A. Muñoz-Juan, A. Carreño, R. Mendoza and J. L. Corchero, *Pharmaceutics*, 2019, **11**.
- 84 V. A. Kickhoefer, Y. Garcia, Y. Mikyas, E. Johansson, J. C. Zhou, S. Raval-Fernandes, P. Minoofar, J. I. Zink, B. Dunn, P. L. Stewart and L. H. Rome, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 4348–4352.
- 85 B. C. Ng, M. Yu, A. Gopal, L. H. Rome, H. G. Monbouquette and S. H. Tolbert, *Nano Lett.*, 2008, **8**, 3503–3509.
- 86 E. Golub, R. H. Subramanian, J. Esselborn, R. G. Alberstein, J. B. Bailey, J. A. Chiong, X. Yan, T. Booth, T. S. Baker and F. A. Tezcan, *Nature*, 2020, **578**, 172–176; N. P. King, J. B. Bale, W. Sheffler, D. E. McNamara, S. Gonen, T. Gonen, T. O. Yeates and D. Baker, *Nature*, 2014, **510**, 103–108.
- 87 N. P. King, J. B. Bale, W. Sheffler, D. E. McNamara, S. Gonen, T. Gonen, T. O. Yeates and D. Baker, *Nature*, 2014, **510**, 103–108.
- 88 N. P. King, W. Sheffler, M. R. Sawaya, B. S. Vollmar, J. P. Sumida, I. Andre, T. Gonen, T. O. Yeates and D. Baker, *Science*, 2012, **336**, 1171–1174.
- 89 A. D. Malay, N. Miyazaki, A. Biela, S. Chakraborti, K. Majsterkiewicz, I. Stupka, C. S. Kaplan, A. Kowalczyk, B. Piette, G. K. A. Hochberg, D. Wu, T. P. Wrobel, A. Fineberg, M. S. Kushwah, M. Kelemen, P. Vavpetic, P. Pelicon, P. Kukura, J. L. P. Benesch, K. Iwasaki and J. G. Heddle, *Nature*, 2019, **569**, 438–442.
- 90 M. Imamura, T. Uchihashi, T. Ando, A. Leifert, U. Simon, A. D. Malay and J. G. Heddle, *Nano Lett.*, 2015, **15**, 1331–1335.
- 91 A. D. Malay, J. G. Heddle, S. Tomita, K. Iwasaki, N. Miyazaki, K. Sumitomo, H. Yanagi, I. Yamashita and Y. Uraoka, *Nano Lett.*, 2012, **12**, 2056–2059.

